Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections
The guidelines also support reusing tenofovir and abacavir in later regimens for improved outcomes, cost savings, and programmatic efficiency
The FDA designation follows visual-function results from the Phase 2 ACUITY trial
The approval is backed by data showing deep, durable responses and manageable tolerability
Tiger Shroff fronts ‘Fit Raho, Hit Raho’ campaign
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
Subscribe To Our Newsletter & Stay Updated
